Patent ID: 7087588

Claim:
A method of reducing at least one of gastrointestinal toxicity, renal toxicity or respiratory toxicity in a patient taking a non-nitroderivative drug selected from the group consisting of the following therapeutic classes: antitumoral other than cisplatin, immunodepressive, antiviral drugs, steroidal antiinflammatory agents, antibiotics, beta-adrenergic antagonists, and enalapril, the method comprising simultaneously, successively or previously administering to the patient an organic compound containing an —ONO 2 group, or an inorganic compound containing an —NO group, wherein the organic or inorganic compound releases NO and activates cGMP synthesis when the organic or inorganic compound is incubated in vitro with vasal endothelium cells or platelets for 5 minutes at a temperature of 37° C., the nitroderivative compounds being administered orally, transdermally or parenterally, wherein the organic compound containing an —ONO 2 group or the inorganic compound containing an —NO group is administered in an amount sufficient to reduce at least one of gastrointestinal toxicity, renal toxicity or respiratory toxicity, and the non-nitroderivative drug is not a NSAID.